Our antibody program consists of proprietary compounds which inhibit complement component C6. The humanized monoclonal antibody CP 010 binds to C6 in circulation. By inhibiting C6 in circulation CP 010 will decrease the level of C6 in CNS to achieve effective inhibition of the formation of Membrane Attack Complex. In animal models C6 inhibition has shown to be safe and effective.